Corporate Development

Since our founding, Geron has focused on strong science and the pursuit of R&D excellence to discover and develop innovative, first-in-class therapies for the treatment of cancer as evidenced through the development of our first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

We enjoy working with like-minded partners who want to join forces to transform the lives of patients with hematologic malignancies by delivering novel therapeutics such as imetelstat that change the course of their disease. We are interested in alliances, partnerships and collaborations that bring complementary capabilities and programs to realize the full potential of imetelstat development and commercialization on a global basis.

To contact our Corporate Development team, please send an e-mail to corpdev@.